Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif

Journal of Virology

Volumn 88, Issue 24, 2014, Pages 14380-14395

  Baig, Tayyba T ^a   Feng, Yuqing ^a   Chelico, Linda ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3 DEOXYCYTIDINE DEAMINASE; APOBEC3B DEOXYCYTIDINE DEAMINASE; APOBEC3G D128K DEOXYCYTIDINE DEAMINASE; APOBEC3H DEOXYCYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; DIMER; TETRAMER; UNCLASSIFIED DRUG; VIF HXB2 PROTEIN; VIF IIIB PROTEIN; VIF PROTEIN; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; PROTEIN BINDING; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANISOTROPY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME SUBSTRATE COMPLEX; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; ROTATIONAL ANISOTROPY; SENSITIVITY ANALYSIS; SEQUENCE ALIGNMENT; STOICHIOMETRY; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN DEGRADATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CYTOSINE DEAMINASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN BINDING; PROTEOLYSIS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84911465713     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02484-14     Document Type: Article

References (77)

1. Refsland EW, Harris RS. 2013. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 371:1-27. http://dx.doi.org/10.1007/978-3-642-37765-5_1.
2. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
4. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038/nature01707.
5. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234. http://dx.doi.org/10.1128/JVI.05238-11.
6. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
7. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
8. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
9. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102:11444-11449. http://dx.doi.org/10.1073/pnas.0502440102.
10. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. 2008. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82:8656-8663. http://dx.doi.org/10.1128/JVI.00767-08.
11. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872. http://dx.doi.org/10.1101/gad.1250204.
12. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299. http://dx.doi.org/10.1016/j.virol.2006.02.002.
13. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550. http://dx.doi.org/10.1016/j.jmb.2007.07.029.
14. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. 2010. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog. 6:e1000925. http://dx.doi.org/10.1371/journal.ppat.1000925.
15. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
16. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
17. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
18. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc.M313093200.
19. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
20. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481:365-370. http://dx.doi.org/10.1038/nature10719.
21. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
22. Binka M, Ooms M, Steward M, Simon V. 2012. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J. Virol. 86:49-59. http://dx.doi.org/10.1128/JVI.06082-11.
23. Aydin H, Taylor MW, Lee JE. 2014. Structure-guided analysis of the human APOBEC3-HIV restrictome. Structure 22:668-684. http://dx.doi.org/10.1016/j.str.2014.02.011.
24. Chen G, He Z, Wang T, Xu R, Yu XF. 2009. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83:8674-8682. http://dx.doi.org/10.1128/JVI.00653-09.
25. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115. http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006.
26. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
27. Yamashita T, Kamada K, Hatcho K, Adachi A, Nomaguchi M. 2008. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 10:1142-1149. http://dx.doi.org/10.1016/j.micinf.2008.06.003.
28. Dang Y, Wang X, Zhou T, York IA, Zheng YH. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552. http://dx.doi.org/10.1128/JVI.00651-09.
29. Huthoff H, Malim MH. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81:3807-3815. http://dx.doi.org/10.1128/JVI.02795-06.
30. Schrofelbauer B, Chen D, Landau NR. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101:3927-3932. http://dx.doi.org/10.1073/pnas.0307132101.
31. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101:3770-3774. http://dx.doi.org/10.1073/pnas.0307713101.
32. Mangeat B, Turelli P, Liao S, Trono D. 2004. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279:14481-14483. http://dx.doi.org/10.1074/jbc.C400060200.
33. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK. 2004. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:5652-5657. http://dx.doi.org/10.1073/pnas.0400830101.
34. Lavens D, Peelman F, Van der Heyden J, Uyttendaele I, Catteeuw D, Verhee A, Van Schoubroeck B, Kurth J, Hallenberger S, Clayton R, Tavernier J. 2010. Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res. 38:1902-1912. http://dx.doi.org/10.1093/nar/gkp1154.
35. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. 2009. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83: 1992-2003. http://dx.doi.org/10.1128/JVI.01621-08.
36. Zhang L, Saadatmand J, Li X, Guo F, Niu M, Jiang J, Kleiman L, Cen S. 2008. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370:113-121. http://dx.doi.org/10.1016/j.virol.2007.08.027.
37. Feng Y, Love RP, Chelico L. 2013. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J. Biol. Chem. 288:6083-6094. http://dx.doi.org/10.1074/jbc.M112.421875.
38. Ooms M, Letko M, Binka M, Simon V. 2013. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS One 8:e57744. http://dx.doi.org/10.1371/journal.pone.0057744.
39. Harari A, Ooms M, Mulder LC, Simon V. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303. http://dx.doi.org/10.1128/JVI.01665-08.
40. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF. 2010. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84:1902-1911. http://dx.doi.org/10.1128/JVI.01509-09.
41. Li MM, Wu LI, Emerman M. 2010. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 84:88-95. http://dx.doi.org/10.1128/JVI.01344-09.
42. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, Sugiura W, Iwatani Y. 2012. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19:1005-1010. http://dx.doi.org/10.1038/nsmb.2378.
43. Smith JL, Pathak VK. 2010. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84:12599-12608. http://dx.doi.org/10.1128/JVI.01437-10.
44. Albin JS, LaRue RS, Weaver JA, Brown WL, Shindo K, Harjes E, Matsuo H, Harris RS. 2010. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285:40785-40792. http://dx.doi.org/10.1074/jbc.M110.173161.
45. Siu KK, Sultana A, Azimi FC, Lee JE. 2013. Structural determinants of HIV-1 Vif susceptibility andDNAbinding in APOBEC3F. Nat. Commun. 4:2593. http://dx.doi.org/10.1038/ncomms3593.
46. Doehle BP, Schafer A, Cullen BR. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288. http://dx.doi.org/10.1016/j.virol.2005.06.005.
47. Marin M, Golem S, Rose KM, Kozak SL, Kabat D. 2008. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82:987-998. http://dx.doi.org/10.1128/JVI.01078-07.
48. Zhou X, Evans SL, Han X, Liu Y, Yu XF. 2012. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One 7:e33495. http://dx.doi.org/10.1371/journal.pone.0033495.
49. Wang X, Zhang H, Lv M, Zuo T, Wu H, Wang J, Liu D, Wang C, Zhang J, Li X, Wu J, Yu B, Kong W, Yu X. 2013. Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-beta binding to Vif. Retrovirology 10:94. http://dx.doi.org/10.1186/1742-4690-10-94.
50. Salter JD, Lippa GM, Belashov IA, Wedekind JE. 2012. Core-binding factor beta increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 51:8702-8704. http://dx.doi.org/10.1021/bi301244z.
51. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319:163-175. http://dx.doi.org/10.1016/j.virol.2003.11.021.
52. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH. 1995. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J. Virol. 69:4166-4172.
53. Ara A, Love RP, Chelico L. 2014. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog. 10:e1004024. http://dx.doi.org/10.1371/journal.ppat.1004024.
54. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3'→5' on single-stranded DNA. Nat. Struct. Mol. Biol. 13:392-399. http://dx.doi.org/10.1038/nsmb1086.
55. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF. 2010. Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285:16195-16205. http://dx.doi.org/10.1074/jbc.M110.107987.
56. Creighton S, Bloom LB, Goodman MF. 1995. Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion by-pass efficiencies. Methods Enzymol. 262:232-256. http://dx.doi.org/10.1016/0076-6879(95)62021-4.
57. Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, Tanaka Y, Ishizaka Y, Nolan D, Mallal S, Sata T, Tokunaga K. 2010. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J. Biol. Chem. 285:35350-35358. http://dx.doi.org/10.1074/jbc.M110.173286.
58. Jameson DM, Ross JA. 2010. Fluorescence polarization/anisotropy in diagnostics and imaging. Chem. Rev. 110:2685-2708. http://dx.doi.org/10.1021/cr900267p.
59. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, Lyubchenko YL. 2011. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286:3387-3395. http://dx.doi.org/10.1074/jbc.M110.195685.
60. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. http://dx.doi.org/10.1371/journal.ppat.1000330.
61. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. 2013. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49:632-644. http://dx.doi.org/10.1016/j.molcel.2012.12.012.
62. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, Hecht FM, Barbour JD, Simon V. 2013. HIV-1 Vif adaptation to human APOBEC3Hhaplotypes. Cell Host Microbe 14:411-421. http://dx.doi.org/10.1016/j.chom.2013.09.006.
63. Love RP, Xu H, Chelico L. 2012. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 287:30812-30822. http://dx.doi.org/10.1074/jbc.M112.393181.
64. Miller JH, Presnyak V, Smith HC. 2007. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4:81. http://dx.doi.org/10.1186/1742-4690-4-81.
65. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407. http://dx.doi.org/10.1128/JVI.77.21.11398-11407.2003.
66. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27. http://dx.doi.org/10.1186/1742-4690-1-27.
67. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K. 2008. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372:136-146. http://dx.doi.org/10.1016/j.virol.2007.10.017.
68. Britan-Rosich E, Nowarski R, Kotler M. 2011. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J. Mol. Biol. 410:1065-1076. http://dx.doi.org/10.1016/j.jmb.2011.03.058.
69. Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J. 2005. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280:8765-8775. http://dx.doi.org/10.1074/jbc.M409309200.
70. Feng Y, Chelico L. 2011. Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J. Biol. Chem. 286:11415-11426. http://dx.doi.org/10.1074/jbc.M110.199604.
71. Ye Y, Rape M. 2009. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell. Biol. 10:755-764. http://dx.doi.org/10.1038/nrm2780.
72. Letko M, Silvestri G, Hahn BH, Bibollet-Ruche F, Gokcumen O, Simon V, Ooms M. 2013. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J. Virol. 87:11861-11871. http://dx.doi.org/10.1128/JVI.01944-13.
73. Zhadina M, McClure MO, Johnson MC, Bieniasz PD. 2007. Ubiquitindependent virus particle budding without viral protein ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 104:20031-20036. http://dx.doi.org/10.1073/pnas.0708002104.
74. Weiss ER, Popova E, Yamanaka H, Kim HC, Huibregtse JM, Gottlinger H. 2010. Rescue of HIV-1 release by targeting widely divergent NEDD4-type ubiquitin ligases and isolated catalytic HECT domains to Gag. PLoS Pathog. 6:e1001107. http://dx.doi.org/10.1371/journal.ppat.1001107.
75. Ooms M, Majdak S, Seibert CW, Harari A, Simon V. 2010. The localization of APOBEC3H variants in HIV-1 virions determines its antiviral activity. J. Virol. 84:7961-7969. http://dx.doi.org/10.1128/JVI.00754-10.
76. Hache G, Abbink TE, Berkhout B, Harris RS. 2009. Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 83:5956-5960. http://dx.doi.org/10.1128/JVI.00045-09.
77. Hache G, Shindo K, Albin JS, Harris RS. 2008. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 18:819-824. http://dx.doi.org/10.1016/j.cub.2008.04.073.